Makhoul, Issam <br/><br/>
Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.  [electronic resource] 

 -  PloS one  2017 
 - e0168550 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0168550  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiopoietin-1--genetics<br/>Angiopoietin-2--genetics<br/>Bevacizumab--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Clinical Trials, Phase II as Topic<br/>Ethnicity<br/>Female<br/>Fibroblast Growth Factor 2--genetics<br/>Gene Frequency<br/>Genotype<br/>Humans<br/>Male<br/>Matrix Metalloproteinase 9--genetics<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neovascularization, Pathologic--genetics<br/>Observational Studies as Topic<br/>Polymorphism, Single Nucleotide<br/>Prospective Studies<br/>Receptor, TIE-2--genetics<br/>Regression Analysis<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--genetics